Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.52 |
| ▸ | LMNA | P02545 | 4/20 | 0.52 |
| ▸ | HTT | P42858 | 3/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | PKM | P14618 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | XBP1 | P17861 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7591620 | 0.96 | MAPT (0.48) | MAPTLMNAHTTPOLBPKM | |
| SCHEMBL7589950 | 0.92 | MAPT (0.52) | MAPTLMNAHTTPOLBPKM | |
| SCHEMBL7590697 | 0.91 | PKM (0.50) | MAPTLMNAHTTPOLBPKM | |
| SCHEMBL7606024 | 0.90 | ALDH1A1 (0.49) | MAPTLMNAHTTPOLBPKM | |
| SCHEMBL593002 | 0.89 | ALDH1A1 (0.48) | MAPTLMNAHTTPOLBPKM | |
| SCHEMBL7594422 | 0.88 | ALDH1A1 (0.50) | MAPTLMNAHTTPOLBPKM | |
| SCHEMBL606362 | 0.88 | PKM (0.48) | MAPTLMNAHTTPOLBPKM | |
| SCHEMBL593814 | 0.88 | PKM (0.48) | MAPTLMNAHTTPOLBPKM | |
| SCHEMBL7590592 | 0.88 | ALDH1A1 (0.47) | MAPTLMNAHTTPOLBPKM | |
| SCHEMBL593085 | 0.87 | MAPT (0.46) | MAPTLMNAHTTPOLBPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2025-10-09 | — | — | US | disclosed |
| US-12336993-B2 | Therapeutic benefit of suboptimally administered chemical compounds | BROWN DENNIS M (US) | 2025-06-24 | — | — | US | disclosed |
| US-20230133044-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2023-05-04 | — | — | US | disclosed |
| US-11491154-B2 | Therapeutic benefit of suboptimally administered chemical compounds | BROWN DENNIS M (US) | 2022-11-08 | — | — | US | disclosed |
| US-11446274-B2 | Use of dianhydrogalactitol or derivatives or analogs thereof for treatment of pediatric central nervous system malignancies | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2022-09-20 | — | — | US | disclosed |
| US-20210251944-A1 | METHODS FOR TREATING A CANCER RESISTANT TO AT LEAST ONE TYROSINE KINASE INHIBITOR | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2021-08-19 | — | — | US | disclosed |
| US-11026914-B2 | Use of dianhydrogalactitol and analogs and derivatives thereof to treat recurrent malignant glioma or progressive secondary brain tumor | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2021-06-08 | — | — | US | disclosed |
| CN-112755193-A | Method of treating malignancies with anti-tyrosine kinase inhibitors using dianhydrogalactitol or a derivative thereof | 德玛医药 | 2021-05-07 | — | — | CN | disclosed |
| EP-2872161-B1 | DIANHYDROGALACTITOL FOR USE IN TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS | DEL MAR PHARMACEUTICALS (CA) | 2020-12-16 | — | — | EP | disclosed |
| US-20190183843-A9 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DELMAR PHARMACEUTICALS, INC. (CA) | 2019-06-20 | — | — | US | disclosed |
| US-8742119-B2 | Pyruvate kinase M2 modulators, therapeutic compositions and related methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8742119-B2 | Pyruvate kinase M2 modulators, therapeutic compositions and related methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8742119-B2 | Pyruvate kinase M2 modulators, therapeutic compositions and related methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| WO-2013056153-A1 | ACTIVATORS OF PYRUVATE KINASE M2 AND METHODS OF TREATING DISEASE | KUNG CHARLES (US) | 2013-04-18 | — | — | WO | disclosed |
| US-20120122885-A1 | PYRUVATE KINASE M2 MODULATORS, THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | AGIOS PHARMACEUTICALS, INC. | 2012-05-17 | — | — | US | disclosed |
| US-20120122885-A1 | PYRUVATE KINASE M2 MODULATORS, THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | AGIOS PHARMACEUTICALS, INC. | 2012-05-17 | — | — | US | disclosed |
| US-20120122885-A1 | PYRUVATE KINASE M2 MODULATORS, THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | AGIOS PHARMACEUTICALS, INC. | 2012-05-17 | — | — | US | disclosed |
| EP-2417123-A2 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | Agios Pharmaceuticals, Inc. (US) | 2012-02-15 | — | — | EP | disclosed |
| WO-2010118063-A2 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | AGIOS PHARMACEUTICALS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010118063-A2 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | AGIOS PHARMACEUTICALS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133044-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | UNG, DPYD, TPMT | MAPT 4222/4885LMNA 4710/4885HTT 3708/4885 |
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | UNG, DPYD, TPMT | MAPT 4222/4885LMNA 4710/4885HTT 3708/4885 |
| US-11491154-B2 | Therapeutic benefit of suboptimally administered chemical compounds | UNG, DPYD, TPMT | MAPT 4222/4885LMNA 4710/4885HTT 3708/4885 |
| US-11446274-B2 | Use of dianhydrogalactitol or derivatives or analogs thereof for treatment of pediatric central nervous system malignancies | DCK, CDC7, DNMT1 | MAPT 4049/4885LMNA 4638/4885HTT 4175/4885 |
| US-20210251944-A1 | METHODS FOR TREATING A CANCER RESISTANT TO AT LEAST ONE TYROSINE KINASE INHIBITOR | DCLRE1B, AIPL1, WHR1 | MAPT 4785/4885LMNA 4045/4885HTT 1266/4885 |
| US-20190183843-A9 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DCK, CDC7, DNMT1 | MAPT 4049/4885LMNA 4638/4885HTT 4175/4885 |
| US-12336993-B2 | Therapeutic benefit of suboptimally administered chemical compounds | UNG, DPYD, TPMT | MAPT 4222/4885LMNA 4710/4885HTT 3708/4885 |
| US-20120122885-A1 | PYRUVATE KINASE M2 MODULATORS, THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | PDK2, PDK1, PDK3 | MAPT 3460/4885LMNA 2033/4885HTT 4353/4885 |
| US-11026914-B2 | Use of dianhydrogalactitol and analogs and derivatives thereof to treat recurrent malignant glioma or progressive secondary brain tumor | DDOST, DAD1, PHGDH | MAPT 1418/4885LMNA 3231/4885HTT 2219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.